Europe

Novartis fails to block repackaged imports of blockbuster treatment
16 October 2025   The court rejected Novartis’s request for emergency measures against a Spanish importer after the pharma company failed to meet the test to enforce an injunction, the winning lawyers told LSIPR.

Latest Features

Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Biotechnology
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
All features


More News

23 September 2025   There are varying national eligibility requirements that distinguish between treatments of and diagnostics for animals and humans; it’s just a question of reformatting ‘method of treatment’ claims, write lawyers from Sterne Kessler.
18 September 2025   A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford.
18 September 2025   From trademark decisions to judicial writing, the IP community is embracing AI but questions loom about quality, precedents, and jurisdictional limits. Muireann Bolger reports from Marques’ annual meeting.
9 September 2025   Wales’ first MP of ethnic minority background brings tech knowledge and expertise to the IP office, which is carrying out two pivotal consultations.
3 September 2025   Carpmaels & Ransford appoints two litigation partners as the UK firm expands its presence in Germany in response to UPC demand.
2 September 2025   A High Court decision clarifies how cross-undertakings work in patent disputes, rejecting claims for exceptional remedies beyond compensation.
1 September 2025   Non-practising entities are controversial, but political winds in the US are shifting and inventors, investors, and operating companies of all stripes should take note, writes Manny Caixeiro of Venable.
More news